Summary-data-based Mendelian Randomization Analysis Identifies Nominal Evidence for Association of N6-Methyladenosine Genetic Variation with Alzheimer’s Disease
Restricted accessResearch articleFirst published online January, 2026
Summary-data-based Mendelian Randomization Analysis Identifies Nominal Evidence for Association of N6-Methyladenosine Genetic Variation with Alzheimer’s Disease
N6-methyladenosine (m6A) is an abundant post-transcriptional RNA modification that critically regulates brain function. Dysregulation of m6A signaling has been implicated in several neurological diseases, including Alzheimer’s disease (AD). However, whether genetic variation associated with the risk of AD is mediated via m6A-dependent gene regulation is currently unknown. Here we investigated the association of m6A with the risk of AD using the summary-data-based Mendelian randomization (SMR) approach. By integrating m6A quantitative trait loci (m6A-QTLs) and genome-wide association study (GWAS) summary data for AD, we identified six nominally significant m6A-AD associations (uncorrected PSMR < 0.05, PHEIDI ≥ 0.01 with ≥5 SNPs), although none remained significant after false discovery rate (FDR) correction. We performed targeted SMR analyses for AD using brain- and blood-based expression QTL summary data, restricting instrumental variables to a set of 18,606 single nucleotide polymorphisms (SNPs) previously identified as m6A-related sites. This analysis identified 75 FDR-significant genes associated with the risk of AD via changes in gene expression (FDR < 0.05, PHEIDI ≥ 0.01 with ≥5 SNPs); however, the instrumental SNPs for these genes showed no enrichment for m6A-QTLs. In summary, we found limited evidence for the direct association of m6A genetic variation with the risk of AD. Larger m6A-QTL datasets will be required to establish whether m6A variation is associated with the risk of AD.
Almeida E SousaI, GrotzingerAD, LawrenceJM, et al.Examining the genetic relationship between Alzheimer’s disease, schizophrenia and their shared risk factors using genomic structural equation modelling. Brain Commun, 2025; 7(2):fcaf112; doi: 10.1093/braincomms/fcaf112
2.
AndoK, KucukaliF, DoeraeneE, et al.; Brain Bank NeuroCEB Neuropathology Network. Alteration of gene expression and protein solubility of the PI 5-phosphatase SHIP2 are correlated with Alzheimer’s disease pathology progression. Acta Neuropathol, 2024; 147(1):94; doi: 10.1007/s00401-024-02745-7
3.
AskenaziM, KavanaghT, PiresG, et al.Compilation of reported protein changes in the brain in Alzheimer’s disease. Nat Commun, 2023; 14(1):4466; doi: 10.1038/s41467-023-40208-x
4.
BellenguezC, KüçükaliF, JansenIE, et al.; CHARGE. New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat Genet, 2022; 54(4):412–436; doi: 10.1038/s41588-022-01024-z
5.
BurgessS, Davey SmithG, DaviesNM, et al.Guidelines for performing Mendelian randomization investigations: Update for summer 2023. Wellcome Open Res, 2019; 4:186; doi: 10.12688/wellcomeopenres.15555.3
6.
CacaceR, SleegersK, Van BroeckhovenC. Molecular genetics of early-onset Alzheimer’s disease revisited. Alzheimers Dement, 2016; 12(6):733–748; doi: 10.1016/j.jalz.2016.01.012
7.
CaoW, HuF, LiY, WangW. Orthodox vs. Paradox: Supporting the central dogma with sugar code. Proteomics, 2025; 17:e70080; doi: 10.1002/pmic.70080
8.
Castro-HernandezR, BerulavaT, MetelovaM, et al.Conserved reduction of m(6)A RNA modifications during aging and neurodegeneration is linked to changes in synaptic transcripts. Proc Natl Acad Sci U S A, 2023; 120(9):e2204933120; doi: 10.1073/pnas.2204933120
9.
CorovicM, Hoch-KraftP, ZhouY, et al.m(6)A in the coding sequence: Linking deposition, translation, and decay. Trends Genet, 2025; 41(11):963–973; doi: 10.1016/j.tig.2025.06.002
10.
DengYY, ZhuHW, XiaoL, et al.Identification of the function and mechanism of m6A reader IGF2BP2 in Alzheimer’s disease. Aging (Albany NY), 2021; 13(21):24086–24100; doi: 10.18632/aging.203652
11.
Diaz-OrtizME, Chen-PlotkinAS. OMICS in neurodegenerative disease: Hope or hype? Trends Genet, 2020; 36(3):152–159; doi: 10.1016/j.tig.2019.12.002
12.
DuBY, ZhangYB, LiangM, et al.N6-methyladenosine (m6A) modification and its clinical relevance in cognitive dysfunctions. Aging (Albany NY), 2021; 13(16):20716–20737; doi: 10.18632/aging.203457
13.
GatzM, PedersenNL, BergS, et al.Heritability for Alzheimer’s disease: The study of dementia in Swedish twins. J Gerontol A Biol Sci Med Sci, 1997; 52(2):M117–M125; doi: 10.1093/gerona/52A.2.M117
14.
GatzM, ReynoldsCA, FratiglioniL, et al.Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry, 2006; 63(2):168–174; doi: 10.1001/archpsyc.63.2.168
15.
GuoF, KangJX, XuJ, et al.Genome-wide identification of m6A-associated single nucleotide polymorphisms in complex diseases of nervous system. Neurosci Lett, 2023; 817:137513; doi: 10.1016/j.neulet.2023.137513
16.
HuB, ShiY, XiongF, et al.Rewired m6A of promoter antisense RNAs in Alzheimer’s disease regulates neuronal genes in 3D nucleome. Nat Commun, 2025; 16(1):5251; doi: 10.1038/s41467-025-60378-0
17.
HuangH, Camats-PernaJ, MedeirosR, et al.Altered expression of the m6A methyltransferase METTL3 in Alzheimer’s disease. eNeuro, 2020; 7(5):ENEURO.0125; doi: 10.1523/ENEURO.0125-20.2020
18.
HuangH, SongRH, WongJJL, et al.The N6-methyladenosine RNA landscape in the aged mouse hippocampus. Aging Cell, 2023; 22(1):e13755; doi: 10.1111/acel.13755
19.
JanSM, FahiraA, ShiYY, et al.Integrative genomic analysis of m6a-SNPs identifies potential functional variants associated with Alzheimer’s disease. ACS Omega, 2023; 8(14):13332–13341; doi: 10.1021/acsomega.3c00696
20.
JansenIE, SavageJE, WatanabeK, et al.Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. Nat Genet, 2019; 51(3):404–413; doi: 10.1038/s41588-018-0311-9
21.
JiangLL, LinWW, ZhangC, et al.Interaction of tau with HNRNPA2B1 and N6-methyladenosine RNA mediates the progression of tauopathy. Mol Cell, 2021; 81(20):4209–4227.e4212; doi: 10.1016/j.molcel.2021.07.038
22.
JingruiW, HaihuiY, JinjinY, et al.IGF2BP2 regulates the progression of Alzheimer’s disease through m6A-mediated NLRP3 inflammasome. Immun Inflamm Dis, 2025; 13(1):e70121; doi: 10.1002/iid3.70121
23.
KunkleBW, Grenier-BoleyB, SimsR, et al.; Genetic and Environmental Risk in AD/Defining Genetic, Polygenic and Environmental Risk for Alzheimer’s Disease Consortium (GERAD/PERADES). Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat Genet, 2019; 51(9):1423–1424; doi: 10.1038/s41588-019-0495-7
24.
KunkleBW, SchmidtM, KleinH-U, et al.Novel Alzheimer disease risk loci and pathways in African American individuals using the African genome resources panel: A meta-analysis. JAMA Neurol, 2021; 78(1):102–620; doi: 10.1001/jamaneurol.2020.3536
25.
LacourA, EspinosaA, LouwersheimerE, et al.Genome-wide significant risk factors for Alzheimer’s disease: Role in progression to dementia due to Alzheimer’s disease among subjects with mild cognitive impairment. Mol Psychiatry, 2017; 22(1):153–160; doi: 10.1038/mp.2016.18
LivnehI, Moshitch-MoshkovitzS, AmariglioN, et al.The m6A epitranscriptome: Transcriptome plasticity in brain development and function. Nat Rev Neurosci, 2020; 21(1):36–51; doi: 10.1038/s41583-019-0244-z
28.
LoyCT, SchofieldPR, TurnerAM, et al.Genetics of dementia. Lancet, 2014; 383(9919):828–840; doi: 10.1016/S0140-6736(13)60630-3
29.
LuoXT, LiHQ, LiangJQ, et al.RMVar: An updated database of functional variants involved in RNA modifications. Nucleic Acids Res, 2021; 49(D1):D1405–D1412; doi: 10.1093/nar/gkaa811
30.
McMahonM, ForesterC, BuffensteinR. Aging through an epitranscriptomic lens. Nat Aging, 2021; 1(4):335–346; doi: 10.1038/s43587-021-00058-y
31.
MewsMA, NajAC, GriswoldAJ, et al.; Alzheimer’s Disease Genetics Consortium. Brain and blood transcriptome-wide association studies identify five novel genes associated with Alzheimer’s disease. J Alzheimers Dis, 2025; 105(1):228–244; doi: 10.1177/13872877251326288
32.
MinKW, ZealyRW, DavilaS, et al.Profiling of m6A RNA modifications identified an age-associated regulation of mRNA stability. Aging Cell, 2018; 17(3):e12753; doi: 10.1111/acel.12753
33.
MostafaviS, GaiteriC, SullivanSE, et al.A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer’s disease. Nat Neurosci, 2018; 21(6):811–819; doi: 10.1038/s41593-018-0154-9
34.
PolancoJC, LiCZ, BodeaLG, et al.Amyloid-β and tau complexity - towards improved biomarkers and targeted therapies. Nat Rev Neurol, 2018; 14(1):22–39; doi: 10.1038/nrneurol.2017.162
35.
QiT, WuY, FangHL, et al.Genetic control of RNA splicing and its distinct role in complex trait variation. Nat Genet, 2022; 54(9):1355–1363; doi: 10.1038/s41588-022-01154-4
36.
QiT, WuY, ZengJ, et al.; eQTLGen Consortium. Identifying gene targets for brain-related traits using transcriptomic and methylomic data from blood. Nat Commun, 2018; 9(1):2282; doi: 10.1038/s41467-018-04558-1
37.
QuX, LinL, LiY, et al.N6-methyladenosine RNA modification regulates microglial phagocytosis in the APP/PS1 mouse model of Alzheimer’s disease. Genes Immun, 2025; 26(5):438–448; doi: 10.1038/s41435-025-00347-1
38.
ShafikAM, ZhangFR, GuoZX, et al.N6-methyladenosine dynamics in neurodevelopment and aging, and its potential role in Alzheimer’s disease. Genome Biol, 2021; 22(1):17; doi: 10.1186/s13059-020-02249-z
39.
ShiHL, WeiJB, HeC. Where, when, and how: Context-dependent functions of RNA methylation writers, readers, and erasers. Mol Cell, 2019; 74(4):640–650; doi: 10.1016/j.molcel.2019.04.025
40.
SunY, BaeYE, ZhuJ, et al.A splicing transcriptome-wide association study identifies novel altered splicing for Alzheimer’s disease susceptibility. Neurobiol Dis, 2023; 184:106209; doi: 10.1016/j.nbd.2023.106209
41.
SunY, ZhouD, RahmanMR, et al.A transcriptome-wide association study identifies novel blood-based gene biomarker candidates for Alzheimer’s disease risk. Hum Mol Genet, 2021; 31(2):289–299; doi: 10.1093/hmg/ddab229
42.
TangX, TenaJ, Di LucenteJ, et al.Transcriptomic and glycomic analyses highlight pathway-specific glycosylation alterations unique to Alzheimer’s disease. Sci Rep, 2023; 13(1):7816; doi: 10.1038/s41598-023-34787-4
43.
TarawnehR, HoltzmanDM. The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment. Cold Spring Harb Perspect Med, 2012; 2(5):a006148; doi: 10.1101/cshperspect.a006148
44.
ThorpJG, MitchellBL, GerringZF, et al.Genetic evidence that the causal association of educational attainment with reduced risk of Alzheimer’s disease is driven by intelligence. Neurobiol Aging, 2022; 119:127–135; doi: 10.1016/j.neurobiolaging.2022.07.011
45.
VosaU, ClaringbouldA, WestraHJ, et al.Large-scale cis-and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. Nat Genet, 2021; 53(9):1300–1310; doi: 10.1038/s41588-021-00913-z
46.
WanYW, Al-OuranR, MangleburgCG, et al.; Accelerating Medicines Partnership-Alzheimer’s Disease Consortium. Meta-analysis of the Alzheimer’s disease human brain transcriptome and functional dissection in mouse models. Cell Rep, 2020; 32(2):107908; doi: 10.1016/j.celrep.2020.107908
47.
WangW. Glycomedicine: The current state of the art. Engineering, 2023; 26:12–15; doi: 10.1016/j.eng.2022.03.009
48.
WidagdoJ, AnggonoV. The m6A-epitranscriptomic signature in neurobiology: From neurodevelopment to brain plasticity. J Neurochem, 2018; 147(2):137–152; doi: 10.1111/jnc.14481
49.
WidagdoJ, WongJJL, AnggonoV. The m6A-epitranscriptome in brain plasticity, learning and memory. Semin Cell Dev Biol, 2022; 125:110–121; doi: 10.1016/j.semcdb.2021.05.023
50.
WightmanDP, JansenIE, SavageJE, et al.; 23andMe Research Team. A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer’s disease. Nat Genet, 2021; 53(9):1276–1282; doi: 10.1038/s41588-021-00921-z
51.
WinbladB, AmouyelP, AndrieuS, et al.Defeating Alzheimer’s disease and other dementias: A priority for European science and society. Lancet Neurol, 2016; 15(5):455–532; doi: 10.1016/S1474-4422(16)00062-4
52.
XuM, ZhangDF, LuoRC, et al.A systematic integrated analysis of brain expression profiles reveals YAP1 and other prioritized hub genes as important upstream regulators in Alzheimer’s disease. Alzheimers Dement, 2018; 14(2):215–229; doi: 10.1016/j.jalz.2017.08.012
53.
ZhangZJ, LuoKX, ZouZY, et al.Genetic analyses support the contribution of mRNA N6-methyladenosine (m6A) modification to human disease heritability. Nat Genet, 2020; 52(9):939–949; doi: 10.1038/s41588-020-0644-z
54.
ZhaoFP, XuY, GaoSC, et al.METTL3-dependent RNA m6A dysregulation contributes to neurodegeneration in Alzheimer’s disease through aberrant cell cycle events. Mol Neurodegener, 2021; 16(1):70; doi: 10.1186/s13024-021-00484-x
55.
ZhaoX, MaC, SunQ, et al.Mettl3 regulates the pathogenesis of Alzheimer’s disease via fine-tuning Lingo2. Mol Psychiatry, 2025; 30(9):4047–4063; doi: 10.1038/s41380-025-02984-4
56.
ZhuZH, ZhangFT, HuH, et al.Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat Genet, 2016; 48(5):481–487; doi: 10.1038/ng.3538
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
